Asimov

We're now shipping out the second book from @AsimovPress (the first commercial book sold in DNA + print). We're packing and shipping thousands of books today! Here are some photos from our at-home assembly line. We think the final product turned out really well.

Our AI-driven cell line and bioprocess design tools consistently deliver 8–11 g/L titers for IgGs and complex multispecifics. Join us tomorrow to learn how we use predictive modeling, rather than trial-and-error, to optimize biologics production: hubs.li/Q03pQVxM0

I'll be live-tweeting (live-posting?) notes from the Boltz-2 release event at MIT. Initial observation: there's a big turnout! Almost every seat is taken at this event, which is rare for academic software releases.

Edward Jenner administered the world's first vaccine, for smallpox, in 1796. At the time, smallpox caused nearly 1/5 of ALL deaths in London. But it was the unsung scientists, Gaston Ramon and Alexander Glenny, who discovered adjuvants and made modern vaccines possible. Story🔻

A human body is built from 30 trillion cells, which come in a multiplicity of shapes and sizes. The smallest cell, a sperm, fills a volume of just 30 µm³, whereas an oocyte boasts a volume of 4,000,000 µm³, making it the largest cell in the human body. Why the huge range?🧵

We're partnering with LOTTE BIOLOGICS, a global CDMO, to scale therapeutics manufacturing. Our customers can now transition seamlessly from cell line development using our CHO EDGE system all the way to large-scale GMP production, with faster cycles. asimov.com/news/lotte-bio…

Beyond excited to announce our deal with Novo Nordisk! Proud of our team who made this possible. The market and molecular complexity of biologics are both growing. Cell engineering tech needs to keep pace to support production of next-gen biologics at global scale.

We’re proud to share that our CHO Edge System has been licensed by Novo Nordisk, a global leader in healthcare innovation. Forward-thinking companies like Novo Nordisk recognize the importance of accessing cutting-edge technologies to advance therapeutic development. We’re…

.@AsimovBio and RevOpsis Therapeutics Ink Licensing Deal for Multispecific-Expressing Cell Line RevOpsis says it is committed to the rapid discovery and development of novel multispecific therapies utilizing its modular RevMod™ Platform. hubs.li/Q02YVHdw0

At least 350+ lentiviral-based gene therapies are in clinical trials. Several have already garnered F.D.A. approval, including a gene therapy for beta-thalassemia, multiple therapies for blood cancers, and another for a rare genetic disease — called CALD — that affects brain…

Today we announced that RevOpsis Therapeutics is licensing our CHO Edge platform to develop and commercialize their first-in-class modular, trispecific biologic molecule for retinal vascular diseases. We’re really excited about this. CHO Edge is an integrated system that enables…